Drug profile · INN
carvedilol
APO-CARVEDILOL
carvedilol (APO-CARVEDILOL) is a adrenergic receptor beta antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — carvedilol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 17
- Data quality
- 0.89
Quick answer
carvedilol (APO-CARVEDILOL) is a adrenergic receptor beta antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor beta antagonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12410474
Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
granted -
US 12377036
Melanin hair dye with thickeners
granted -
US 12370267
Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
granted -
US 12351574
Selective ligands for modulation of GIRK channels
granted -
US 12337019
Vehicles for applying bacteria to skin, scalp, and hair
granted -
US 12331279
Systems for producing cellular immunotherapeutics and methods of use thereof
granted -
US 12319711
Spherical nucleic acids with tailored and active protein coronae
granted -
US 12291533
Substituted fused pyrimidine compounds and uses thereof
granted -
US 12281310
Use of trinucleotide repeat RNAs to treat cancer
granted -
US 12264344
Protein/oligonucleotide core-shell nanoparticle therapeutics
granted -
US 12252522
Myokines for treating cell proliferative and metabolic diseases and disorders
granted -
US 12252492
Substituted fused pyrrolo-diazepinones and uses thereof
granted -
US 12247063
Cell surface modification by coating with peptide amphiphiles (PAs)
granted -
US 12233081
Hygromycin a compounds and methods of treating spirochete diseases
granted -
US 12233080
Lipotechoic acid for immune modulation
granted -
US 12226444
Compositions comprising peptides comprising variant kinesin light chain 1 and cell-penetrating peptides
granted -
US 12226410
Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
granted -
US 12214076
Drug delivery vehicles for atherosclerosis nanomedicine
granted -
US 12174205
Phosphatidylethanolamine-specific probes
granted -
US 12171854
Heterocyclic-dithiol click chemistry
granted
Frequently asked questions
What is carvedilol?
carvedilol (APO-CARVEDILOL) is a adrenergic receptor beta antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for carvedilol?
APO-CARVEDILOL is a marketed brand name for carvedilol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carvedilol?
carvedilol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.